EyePoint Stock

EyePoint EBIT

The EBIT of EyePoint (EYPT) as of Jul 26, 2026 is -243.43 M USD. In the previous year, EBIT was -145.85 M USD — a change of 66.90% (lower).

EBIT

-243.43 MUSD

YoY

66.90%

Last updated:

In 2026, EyePoint's EBIT was -243.43 M USD, a 66.90% increase from the -145.85 M USD EBIT recorded in the previous year.

The EyePoint EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2020
-38.14 base
Jan 1, 2021
-53.21 base
Jan 1, 2022
-99.64 base
Jan 1, 2023
-75.07 base
Jan 1, 2024
-145.85 base
Jan 1, 2025
-243.43 base
Jan 1, 2026 (e)
-272.87 base
Jan 1, 2027 (e)
-276.04 base
YEAREBIT (M USD)
2027 est -276.04
2026 est -272.87
2025 -243.43
2024 -145.85
2023 -75.07
2022 -99.64
2021 -53.21
2020 -38.14
2019 -50.62
2018 -26.27
2017 -18.58
2016 -21.77
2015 6.42
2014 -13.49
2013 -12.03
2012 -25.21
2011 -10.00
2010 9.09
2009 -4.64
2008 -24.90
2007 -35.54
2006 -27.68
Access this data via the Eulerpool API

EyePoint Revenue

EyePoint Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
34.44 M USD
-38.14 M USD
-45.39 M USD
Jan 1, 2021
36.94 M USD
-53.21 M USD
-58.42 M USD
Jan 1, 2022
41.40 M USD
-99.64 M USD
-102.25 M USD
Jan 1, 2023
46.02 M USD
-75.07 M USD
-70.80 M USD
Jan 1, 2024
43.27 M USD
-145.85 M USD
-130.87 M USD
Jan 1, 2025
31.37 M USD
-243.43 M USD
-231.96 M USD
Jan 1, 2026 (e)
1.77 M USD
-272.87 M USD
-200.11 M USD
Jan 1, 2027 (e)
32.75 M USD
-276.04 M USD
-171.31 M USD

EyePoint Margins

EyePoint stock margins

The EyePoint margin analysis displays the gross margin, EBIT margin, as well as the profit margin of EyePoint. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for EyePoint.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
83.09 %
-110.74 %
-131.82 %
Jan 1, 2021
77.86 %
-144.05 %
-158.14 %
Jan 1, 2022
79.89 %
-240.65 %
-246.97 %
Jan 1, 2023
89.93 %
-163.13 %
-153.84 %
Jan 1, 2024
91.42 %
-337.06 %
-302.43 %
Jan 1, 2025
93.41 %
-775.98 %
-739.42 %
Jan 1, 2026 (e)
93.41 %
-15,387.41 %
-11,283.98 %
Jan 1, 2027 (e)
93.41 %
-842.92 %
-523.11 %

EyePoint Stock analysis

What does EyePoint do? EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing EyePoint's EBIT

EyePoint's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of EyePoint's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

EyePoint's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in EyePoint’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about EyePoint stock

EBIT of EyePoint is -243.43 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — EyePoint

All Key Metrics — EyePoint